2012-2016年美国接种灭活Vero细胞培养来源的日本脑炎疫苗后的不良事件
分析了2012年5月1日至2016年4月30日VAERS收到的119份接种JE-VC后不良事件报告,报告率为每10万剂14.8例,严重事件9例(每10万剂1.1例),最常见为超敏反应24例(每10万剂3.0例),结论支持JE-VC总体良好的安全性。
要点
- 4年内共119份不良事件报告,报告率每10万剂14.8例,严重事件9例(8%),报告率每10万剂1.1例。
- 最常见事件为超敏反应24例(20%),报告率每10万剂3.0例;报告1例过敏反应。
- 神经系统事件10例(8%),报告率每10万剂1.2例,其中2例分类为癫痫发作。
核心结论
- 这些数据继续支持JE-VC总体良好的安全性特征。
- 不良事件报告率与先前分析相似。
- 儿童不良事件报告率无法计算,但该年龄组报告事件数量少。
- 该相对较新疫苗的上市后不良事件监测对于监测报告率和识别可能的罕见严重事件仍很重要。
研究设计与样本
- 审查2012年5月1日至2016年4月30日期间接种JE-VC后向美国疫苗不良事件报告系统(VAERS)报告的不良事件。
- 使用802,229剂分发的剂量计算不良事件报告率。
主要发现
- 4年期间共收到119份不良事件报告,报告率为每10万剂分发剂量14.8例。
- 9份(8%)不良事件被分类为严重,报告率为每10万剂分发剂量1.1例。
- 最常见报告事件为超敏反应(n=24;20%),报告率为每10万剂分发剂量3.0例;报告1例过敏反应事件。
- 报告10份(8%)神经系统事件,报告率为每10万剂分发剂量1.2例;2份事件被分类为癫痫发作。
- 63份(53%)不良事件发生在接种第一剂JE-VC后;80份(67%)不良事件发生在JE-VC与其他疫苗同时接种后;11份(9%)不良事件报告于儿童,其中1份被认为严重。
局限性
- 儿童不良事件报告率无法计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In March 2009, the U.S. Food and Drug Administration licensed an inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [IXIARO®]) for use in persons aged ≥17 years. In 2013, licensure was extended to include children aged ≥2 months. A previous analysis reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from May 2009 through April 2012. METHODS: We reviewed adverse events reported to VAERS following JE-VC administered from May 1, 2012 through April 30, 2016. Adverse event reporting rates were calculated using 802,229 doses distributed. RESULTS: During the 4-year period, 119 adverse event reports were received for a reporting rate of 14.8 per 100,000 doses distributed. Nine (8%) adverse events were classified as serious for a reporting rate of 1.1 per 100,000 distributed. The most commonly reported event was hypersensitivity (n = 24; 20%) for a rate of 3.0 per 100,000 doses distributed; 1 anaphylaxis event was reported. Ten (8%) neurologic events were reported for a rate of 1.2 per 100,000 doses distributed; 2 events were classified as seizures. Sixty-three (53%) adverse events occurred after a first dose of JE-VC. Eighty (67%) adverse events occurred after administration of JE-VC with other vaccines. Eleven (9%) adverse events were reported in children; 1 was considered serious. CONCLUSIONS: These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events.
引用
- Walker WL, Hills SL, Miller ER, et al. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016. Vaccine. 2018. PMID: 29891351. doi:10.1016/j.vaccine.2018.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。